Noriaki Ishida - Daiichi Sankyo Insider

DSNKY -- USA Stock  

USD 42.87  0.33  0.78%

  VP
We currently do not have informatin regarding Noriaki Ishida. This executive tanure with Daiichi Sankyo Company Limited is not currenlty determined.
  VP Since 2016      
81 3 6225 1111  http://www.daiichisankyo.com

Management Efficiency

The company has return on total asset (ROA) of 2.15 % which means that it generated profit of $2.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 4.58 % meaning that it generated $4.58 on every $100 dollars invested by stockholders.
The company has accumulated 2.55 B in total debt with debt to equity ratio (D/E) of 23.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Daiichi Sankyo Company Limited has Current Ratio of 3.76 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 1 records

VP Since

Michael UllmannJohnson Johnson
2016

Entity Summary

Daiichi Sankyo Company, Limited researches, develops, manufactures, imports, and markets pharmaceutical products worldwide. The company was founded in 1899 and is headquartered in Tokyo, Japan. Daiichi Sankyo is traded on OTC Market in USA.Daiichi Sankyo Company Limited (DSNKY) is traded on OTC Market in USA. It is located in 3-5-1, Nihonbashi-honcho and employs 14,446 people.

Daiichi Sankyo Limited Leadership Team

Glenn Gormley, Senior Managing Executive Officer, Chief Director of Research & Development
Masahiko Ohtsuki, Executive Officer, Senior Director of Research in Main Research & Development Unit
Joji Nakayama, CEO and President and Representative Director
Takeshi Ogita, Senior Managing Executive Officer, Chief Director of General Affairs and Human Resources, Chief Director of Vaccine Business in Japan Company, Director
Shinichi Terano, Executive Officer, Manager of Tokyo Office in Main Medical Sales Unit of Japan Company
Sunao Manabe, Managing Executive Officer and Presidentident of Japan Company, Chief Director of Business Promotion, Director
Takeshi Hamaura, Executive Officer, Chief Director of Pharmaceutical Technology, Director of CMC Planning
Toshiaki Sai, Executive Officer, Director of Product Strategy in Main Strategy Unit
Tsuguya Fukui, Independent Director
Hiroshi Toda, Independent Director
Hiroshi Hirabayashi, Independent Director
Katsumi Fujimoto, Executive Officer, Chief Director of Medicine Manufacturing Technology
Shinichi Tobita, Executive Officer, Director of Marketing in Main Pharmaceutical Sales Unit
Kentaro Murakawa, Executive Officer, Manager of Tokyo Office in Main Pharmaceutical Sales Unit
Yuichi Kubo, VP of Bus. Devel. andLicensing Department - Corporate Strategy Division and Corporate Officer
Ryoichi Watanabe, Director of Finance and Accounting
Noriaki Ishida, VP of Corporate Communications Department - Corporate Management Division and Executive Officer
Toshiaki Tojo, Executive Officer, Director of Credibility Assurance
Naoyuki Kishi, Executive Officer, Chief Director of Pharmaceutical Technology
Naoki Adachi, Independent Director
Shuji Handa, Managing Executive Officer and Presidentident of ASCA Company
Noritaka Uji, Independent Director
Masahiro Ohtsuki, Executive Officer, Director of Main Research Development Unit Research In Charge
Yoshihiro Aoyagi, VP of Legal Affairs Department, General Affairs and HR Division and Corporate Officer
Junichi Fukute, Executive Officer, Director of Supply Chain Planning in Main Supply Chain Unit
Kazuo Sato, Executive Officer, Director of License in Main Strategy Unit
Manabu Sakai, Head of Corporate Management Division, Executive VP and Representative Director
Kohei Wada, Executive Officer, Director of Main Research Development Unit Development In Charge
Hideyuki Hirano, Executive Officer, Director of Sales Planning in Main Pharmaceutical Sales Unit
Koji Ogawa, Executive Officer and Presidentident of ASCA Company
Yuki Sato, Head of Legal Affairs and CSR Division, Head of General Affairs and HR Division, Head of Supply Chain Division, Executive VP and Representative Director
Hironobu Furuta, Executive Officer, Director of Human Resources in Main General Affairs Unit
Ryoji Nagasaka, Executive Officer, Manager of Kyushu Office in Main Medical Sales of Japan Company
Satoru Kimura, Head of Sales and Marketing Division and Executive Officer
Junichi Koga, Executive Officer, Senior Director of Bio
Shoji Hirashima, Executive Officer, Director of Business Promotion in Main Business Strategy Unit
Norimasa Kamura, Director of Human Resources, Executive Officer
Kentaro Takamura, Director of Finance & Accounting
Hirosumi Izawa, Executive Officer, Chief Director of Reliability Guarantee
Kazuyuki Watanabe, Executive Officer
Kazunori Hirokawa, Senior Managing Executive Officer, Chief Director of Strategy, Chief Director of Japan Company Business Promotion, Director
Koichi Akahane, Executive Officer, Director of Research Development Planning in Main Research and Development Unit
Kunio Ishihara, Independent Director
Kenji Katsumi, Executive Officer, Director of General Affairs & Procurement in Main General Affairs Unit

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Analyst Recommendations

Daiichi Sankyo Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Daiichi Sankyo and Johnson Johnson. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Search macroaxis.com